Sen. Grassley seeks transparency in FDA review of heart health risks with diabetes drug

WASHINGTON — Sen. Chuck Grassley has asked the Food and Drug Administration to respond to accounts that an agency-convened drug safety oversight board voted earlier this month to keep Avandia on the market by a one-vote margin amid agency considerations of a second warning for the drug label about heart attack risks. Grassley said sources […]

Grassley Releases Participant List for Non-profit Hospital Roundtable

Participant list for October 30, 2007, Non-profit Hospital Roundtable • David Benfer Chief Executive Officer Saint Raphael Healthcare System New Haven, CT • Paula Bussard Senior Vice President, Policy and Regulatory Services The Hospital and Healthsystem Association of Pennsylvania Harrisburg, PA • John Colombo Albert E. Jenner, Jr. Professor of Law University of Illinois College […]

Sen. Grassley’s comment on the House vote on a second SCHIP compromise bill

M E M O R A N D U M TO: Reporters and EditorsFR: Jill Gerber for Sen. Grassley, 4-6522; Jared Whitley for Sen. Hatch, 4-5251RE: House vote on SCHIP legislationDA: Thursday, October 25, 2007 Sens. Chuck Grassley and Orrin Hatch issued the comments below about the outcome ofthe vote this afternoon in the House […]

“Mother of Tax Bills” Could Bring Mother Lode of Economic Trouble

Sen. Chuck Grassley, ranking member of the Committee on Finance, today made the following comment on the tax reform proposal from Rep. Charles Rangel, chairman of the House Committee on Ways and Means. “I appreciate that Chairman Rangel is revving up the debate on two critical issues, AMT repeal and corporate tax reform. These are […]

Sen. Grassley comments on FDA letter to drug maker about flawed Ketek study

Sen. Chuck Grassley issued the comment below about the warning letter (posted at http://www.fda.gov/cder/warn/warn2007) sent yesterday by the Food and Drug Administration to Sanofi-Aventis U.S. LLC regarding “objectionable conditions” found with the drug manufacturer’s conduct of the large safety study (3014) it submitted to make the case for FDA approval of the antibiotic Ketek. Sen. […]

Grassley: House Tax Proposal Could Undermine U.S. Companies’ Competitiveness

In 2004, Congress enacted legislation to repeal the Foreign Sales Corporation-Extraterritorial Income tax regime that was ruled a prohibited export subsidy by the World Trade Organization. By itself, repealing that regime would have caused a $50 billion tax increase on U.S. manufacturers over 10 years, so Congress also enacted an across-the-board effective tax rate cut […]

Grassley Announces Roundtable on Staff Discussion Draft on Non-profit Hospitals

WASHINGTON – Sen. Chuck Grassley, ranking member of the Committee on Finance, today announced a roundtable to discuss the committee minority staff discussion draft of potential reforms involving non-profit hospitals. The roundtable will be held on Tuesday, Oct. 30, from 2 p.m. to 5 p.m., in 215 Dirksen Senate Office Building. The roundtable will be […]

Grassley, Specter Introduce Transparency in Medical Device Pricing Act

WASHINGTON – Sen. Chuck Grassley, ranking member of the Committee on Finance, and Sen. Arlen Specter, ranking member of the Judiciary Committee, today introduced legislation to inject some much-needed transparency into the prices medical device suppliers charge hospitals participating in federal health care programs. The bill is meant to ensure that hospitals can provide care […]